Kukje Pharma Statistics

Total Valuation

Kukje Pharma has a market cap or net worth of KRW 95.91 billion. The enterprise value is 116.67 billion.

Market Cap	95.91B
Enterprise Value	116.67B

Important Dates

The next estimated earnings date is Wednesday, May 14, 2025.

Earnings Date	May 14, 2025
Ex-Dividend Date	Mar 13, 2025

Share Statistics

Kukje Pharma has 20.36 million shares outstanding. The number of shares has increased by 0.53% in one year.

Current Share Class	n/a
Shares Outstanding	20.36M
Shares Change (YoY)	+0.53%
Shares Change (QoQ)	+0.00%
Owned by Insiders (%)	12.78%
Owned by Institutions (%)	8.39%
Float	12.69M

Valuation Ratios

The trailing PE ratio is 18.42.

PE Ratio	18.42
Forward PE	n/a
PS Ratio	0.61
PB Ratio	1.07
P/TBV Ratio	1.08
P/FCF Ratio	93.22
P/OCF Ratio	24.34
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.78, with an EV/FCF ratio of 113.40.

EV / Earnings	22.41
EV / Sales	0.75
EV / EBITDA	11.78
EV / EBIT	17.41
EV / FCF	113.40

Financial Position

The company has a current ratio of 2.00, with a Debt / Equity ratio of 0.33.

Current Ratio	2.00
Quick Ratio	1.13
Debt / Equity	0.33
Debt / EBITDA	2.98
Debt / FCF	28.68
Interest Coverage	5.56

Financial Efficiency

Return on equity (ROE) is 5.97% and return on invested capital (ROIC) is 3.57%.

Return on Equity (ROE)	5.97%
Return on Assets (ROA)	2.55%
Return on Invested Capital (ROIC)	3.57%
Return on Capital Employed (ROCE)	4.89%
Revenue Per Employee	641.24M
Profits Per Employee	21.33M
Employee Count	244
Asset Turnover	0.95
Inventory Turnover	3.39

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -3.91% in the last 52 weeks. The beta is 0.95, so Kukje Pharma's price volatility has been similar to the market average.

Beta (5Y)	0.95
52-Week Price Change	-3.91%
50-Day Moving Average	4,774.90
200-Day Moving Average	5,385.58
Relative Strength Index (RSI)	51.67
Average Volume (20 Days)	141,693

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Kukje Pharma had revenue of KRW 156.46 billion and earned 5.21 billion in profits. Earnings per share was 255.64.

Revenue	156.46B
Gross Profit	82.50B
Operating Income	6.70B
Pretax Income	6.61B
Net Income	5.21B
EBITDA	9.90B
EBIT	6.70B
Earnings Per Share (EPS)	255.64

Full Income Statement

Balance Sheet

The company has 8.75 billion in cash and 29.51 billion in debt, giving a net cash position of -20.76 billion or -1,019.36 per share.

Cash & Cash Equivalents	8.75B
Total Debt	29.51B
Net Cash	-20.76B
Net Cash Per Share	-1,019.36
Equity (Book Value)	89.55B
Book Value Per Share	4,397.39
Working Capital	28.43B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 3.94 billion and capital expenditures -2.91 billion, giving a free cash flow of 1.03 billion.

Operating Cash Flow	3.94B
Capital Expenditures	-2.91B
Free Cash Flow	1.03B
FCF Per Share	50.53

Full Cash Flow Statement

Margins

Gross margin is 52.73%, with operating and profit margins of 4.28% and 3.33%.

Gross Margin	52.73%
Operating Margin	4.28%
Pretax Margin	4.22%
Profit Margin	3.33%
EBITDA Margin	6.33%
EBIT Margin	4.28%
FCF Margin	0.66%

Dividends & Yields

This stock pays an annual dividend of 30.00, which amounts to a dividend yield of 0.65%.

Dividend Per Share	30.00
Dividend Yield	0.65%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	5
Payout Ratio	n/a
Buyback Yield	-0.53%
Shareholder Yield	0.12%
Earnings Yield	5.43%
FCF Yield	1.07%

Dividend Details

Stock Splits

The last stock split was on March 17, 2023. It was a forward split with a ratio of 1.05.

Last Split Date	Mar 17, 2023
Split Type	Forward
Split Ratio	1.05

Scores

Kukje Pharma has an Altman Z-Score of 2.19. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.19
Piotroski F-Score	n/a